Amplia today announced that following the review of available safety, pharmacokinetic and pharmacodynamic data by the Safety Review Committee, dose escalation and recruitment of another patient cohort into the trial has been approved.
This first stage of the ACCENT trial is designed to identify the most suitable dose of AMP945 to combine with gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer. Dose escalation of AMP945 will continue until either a dose‑limiting safety signal is identified or the pharmacodynamic effect of AMP945 reaches a plateau.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“We are delighted that the data we have collected for AMP945, when used in combination with gemcitabine and nab‑paclitaxel, supports dose escalation in the second cohort of patients. The performance of AMP945 appears to be tracking well, and is aligned with our expectations based on the excellent profile AMP945 demonstrated in the previous Phase 1 clinical trial in healthy volunteers.”
Click here to read today’s ASX release.
